Cytokinetics (CYTK) Net Cash Flow Growth (1y) (2011 - 2026)

Cytokinetics (CYTK) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 172.72%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 53.21%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 75.60%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 1,421.76%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 149.49%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -100.75%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -104.22%
10 Cytokinetics 10.31 Bn 9.14 Bn 25.89 Mn 3,866.61%

Historic Data

Download Data
DateValue
Jun 30, 2026 3,866.61%
Mar 31, 2026 137.13%
Dec 31, 2025 -316.31%
Sep 30, 2025 206.19%
Jun 30, 2025 -95.47%
Mar 31, 2025 -401.91%
Dec 31, 2024 257.08%
Sep 30, 2024 -560.92%
Jun 30, 2024 305.10%
Mar 31, 2024 -80.78%
Dec 31, 2023 134.19%
Sep 30, 2023 146.32%
Jun 30, 2023 -56.95%
Mar 31, 2023 1,207.47%
Dec 31, 2022 -276.69%
Sep 30, 2022 -76.39%
Jun 30, 2022 -192.89%
Mar 31, 2022 107.18%
Dec 31, 2021 118.76%
Sep 30, 2021 -61.76%